Wegovy FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 17, 2023.
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an adjunct to diet and exercise for chronic weight management.
- Wegovy is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:
- adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
- pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity).
- Wegovy works by decreasing caloric intake by activating GLP-1 receptors, which are present in several areas of the brain involved in appetite regulation.
- Wegovy is administered by subcutaneous injection once weekly, with or without meals.
- The Wegovy product label carries a boxed warning for an increased risk of thyroid C-cell tumors.
- Common adverse reactions include nausea, diarrhea, vomiting, constipation, and abdominal pain.
Development timeline for Wegovy
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.